The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Open accessAbstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both vaccines encode the same full-length, pre-fusion stabilized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein13,14 and are encapsulated in lipid nanoparticles (LNPs) with identical composition.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stabilizing coronavirus spike proteins by substituting two prolines at the top of heptad repeat 1 prevents structural rearrangements of the fusion (S2) subunit.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, S-2P conformational stability translates into greater immunogenicity,27-29 based on preservation of neutralization-sensitive epitopes at the apex of the prefusion molecule, as shown for respiratory syncytial virus F glycoprotein,30 and improved protein expression,27 which is particularly advantageous for gene-based antigen delivery.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
In the citing paper
“Immune responses are improved by introducing two consecutive proline residues (2P), which are known to retain the full-length S protein in the prefusion conformation.64,65”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Comparative Protein Structure Modeling Using MODELLER
Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Cited by
Sorted by citations
Items 401–500 of 1,000
Saville, J. W., Berezuk, A., Srivastava, S. S., & Subramaniam, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01062 · Cited by 32
Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection
Islamuddin, M., Mustfa, S. A., Ullah, S. N. M. N., Omer, U., Kato, K., & Parveen, S. (2022) · Inflammation · doi:10.1007/s10753-022-01651-y · Cited by 31
Hutchinson, G. B., Abiona, O. M., Ziwawo, C. T., Werner, A. P., Ellis, D., Tsybovsky, Y., Leist, S. R., Palandjian, C., West, A., Fritch, E. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41661-4 · Cited by 29
Self-citationLaing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Coggins, S. A., Samuels, E. C., Phogat, S., Yan, L., Moreno, N., Coles, C., et al. (2021) · medRxiv · doi:10.1101/2021.02.10.21251518 · Cited by 29
Chuang, G., Lai, Y., Boyington, J. C., Cheng, C., Geng, H., Narpala, S., Rawi, R., Schmidt, S. D., Tsybovsky, Y., Verardi, R., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00074-20 · Cited by 27
Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review
Everest, H., Stevenson-Leggett, P., Bailey, D., Bickerton, E., & Keep, S. (2022) · Viruses · doi:10.3390/v14020351 · Cited by 28
Barreiro, A., Prenafeta, A., Bech-Sabat, G., Roca, M., Perozo Mur, E., March, R., González-González, L., Madrenas, L., Corominas, J., Fernández, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106126 · Cited by 28
Ivanochko, D., Fabra-García, A., Teelen, K., van de Vegte‐Bolmer, M., van Gemert, G., Newton, J. C., Semesi, A., de Bruijni, M. H. C., Bolscher, J. M., Ramjith, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.013 · Cited by 28
Automatic and accurate ligand structure determination guided by cryo-electron microscopy maps
Muenks, A., Zepeda, S., Zhou, G., Veesler, D., & DiMaio, F. (2023) · Nature Communications · doi:10.1038/s41467-023-36732-5 · Cited by 28
Prefusion stabilization of the Hendra and Langya virus F proteins
Byrne, P. O., Blade, E. G., Fisher, B. E., Ambrozak, D. R., Ramamohan, A. R., Graham, B. S., Loomis, R. J., & McLellan, J. S. (2024) · Journal of Virology · doi:10.1128/jvi.01372-23 · Cited by 28
Self-citationCryo-EM Studies of Virus-Antibody Immune Complexes
Li, N., Li, Z., Fu, Y., & Cao, S. (2020) · Virologica Sinica · doi:10.1007/s12250-019-00190-5 · Cited by 27
Structural basis of SARS-CoV-2 spike protein induced by ACE2
Meirson, T., Bomze, D., & Markel, G. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa744 · Cited by 27
Law, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 27
Martí, D., Torras, J., Bertrán, O., Turón, P., & Alemán, C. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.037 · Cited by 27
A Structural View at Vaccine Development against M. tuberculosis
Romanò, M., Squeglia, F., Kramarska, E., Barra, G., Choi, H., Kim, H., Ruggiero, A., & Berisio, R. (2023) · Cells · doi:10.3390/cells12020317 · Cited by 27
Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants
Tan, S., Zhao, J., Hu, X., Li, Y., Wu, Z., Lu, G., Yu, Z., Du, B., Liu, Y., Li, L., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.11.024 · Cited by 25
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Modjarrad, K., Che, Y., Chen, W., Wu, H., Couto, C. I. C., Muik, A., Maddur, M. S., Tompkins, K. R., Martinez, L. T., Cai, H., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01013-9 · Cited by 24
Kim, Y., Lee, H., Park, K., Park, S., Lim, J., So, M. K., Woo, H., Ko, H., Lee, J. M., Lim, S. H., et al. (2019) · Antibodies · doi:10.3390/antib8030042 · Cited by 27
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Szurgot, I., Hanke, L., Sheward, D. J., Vidakovics, L. P., Murrell, B., McInerney, G. M., & Liljeström, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-82498-5 · Cited by 26
Olmedillas, E., Mann, C. J., Peng, W., Wang, Y.-T., Díaz-Avalos, R., Bedinger, D., Valentine, K. M., Shafee, N., Schendel, S. L., Yuan, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.441046 · Cited by 23
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
Current advances in the detection of COVID-19 and evaluation of the humoral response
Huergo, M. A., & Thanh, N. T. K. (2020) · The Analyst · doi:10.1039/d0an01686a · Cited by 27
Frantz, P. N., Barinov, A., Ruffié, C., Combredet, C., Najburg, V., de Melo, G. D., Larrous, F., Kergoat, L., Teeravechyan, S., Jongkaewwattana, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26506-2 · Cited by 26
Ebel, H., Benecke, T., & Vollmer, B. (2022) · Viruses · doi:10.3390/v14081816 · Cited by 26
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Miao, G., Chen, Z., Cao, H., Wu, W., Chu, X., Liu, H., Zhang, L., Zhu, H., Cai, H., Lu, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114208 · Cited by 27
Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era
Sharma, M., Krammer, F., García‐Sastre, A., & Tripathi, S. (2019) · Vaccines · doi:10.3390/vaccines7030089 · Cited by 27
Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
Fedechkin, S. O., George, N. L., Nuñez Castrejon, A. M., Dillen, J. R., Kauvar, L. M., & DuBois, R. M. (2020) · Journal of Virology · doi:10.1128/jvi.01879-19 · Cited by 26
Steffen, T. L., Stone, E. T., Hassert, M., Geerling, E., Grimberg, B. T., Espino, A. M., Pantoja, P., Climent, C., Hoft, D. F., George, S. L., et al. (2020) · doi:10.1101/2020.08.21.261727 · Cited by 25
Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses
Bedi, R., Bayless, N. L., & Glanville, J. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020722-041304 · Cited by 26
Understanding Fc function for rational vaccine design against pathogens
Bowman, K. A., Kapłonek, P., & McNamara, R. P. (2023) · mBio · doi:10.1128/mbio.03036-23 · Cited by 26
A modular cell-free protein biosensor platform using split T7 RNA polymerase
McSweeney, M. A., Patterson, A. T., Loeffler, K., de Larrea, R. C. L., McNerney, M. P., Kane, R. S., & Styczynski, M. P. (2025) · Science Advances · doi:10.1126/sciadv.ado6280 · Cited by 25
A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2
Vollmer, B., Ebel, H., Rees, R., Nentwig, J., Mulvaney, T., Schünemann, J., Krull, J., Topf, M., Görlich, D., & Grünewald, K. (2025) · Nature · doi:10.1038/s41586-025-09438-5 · Cited by 25
del Moral-Sánchez, I., Russell, R. A., Schermer, E. E., Cottrell, C. A., Allen, J. D., de la Peña, A. T., LaBranche, C. C., Kumar, S., Crispin, M., Ward, A. B., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00446-4 · Cited by 25
Self-citationAntibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Brinkkemper, M., Veth, T. S., Brouwer, P. J. M., Turner, H. L., Poniman, M., Burger, J. A., Bouhuijs, J. H., Olijhoek, W., Bontjer, I., Snitselaar, J. L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105649 · Cited by 25
Self-citationRabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26
Loss of FCoV-23 spike domain 0 enhances fusogenicity and entry kinetics
Tortorici, M. A., Choi, A., Gibson, C. A., Lee, J., Brown, J. T., Stewart, C., Joshi, A., Harari, S., Willoughby, I., Treichel, C., et al. (2025) · Nature · doi:10.1038/s41586-025-09155-z · Cited by 24
Momtazi‐Borojeni, A. A., Banach, M., Reiner, Ž., Pirro, M., Bianconi, V., Al‐Rasadi, K., & Sahebkar, A. (2020) · Angiology · doi:10.1177/0003319720952284 · Cited by 24
Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus
Yu, J., Sreenivasan, C. C., Uprety, T., Gao, R., Huang, C., Lee, E. J., Lawson, S. R., Nelson, J. К., Christopher‐Hennings, J., Kaushik, R. S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00283-x · Cited by 24
Seephetdee, C., Buasri, N., Bhukhai, K., Srisanga, K., Manopwisedjaroen, S., Lertjintanakit, S., Phueakphud, N., Pakiranay, C., Kangwanrangsan, N., Srichatrapimuk, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9050498 · Cited by 22
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]
Jawalagatti, V., Kirthika, P., & Lee, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884862 · Cited by 24
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 26
A platform technology for generating subunit vaccines against diverse viral pathogens
Young, A., Isaacs, A., Scott, C. A. P., Modhiran, N., McMillan, C. L. D., Cheung, S. T. M., Barr, J. A., Marsh, G. A., Thakur, N., Bailey, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963023 · Cited by 25
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 30
Jackson-Thompson, B. M., Goguet, E., Laing, E. D., Olsen, C. H., Pollett, S. D., Hollis-Perry, M., Maiolatesi, S. E., Illinik, L., Ramsey, K. F., Reyes, A. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06233-1 · Cited by 23
Polak, K., Greze, N., Lachat, M., Merle, D., Chiumento, S., Bertrand‐Gaday, C., Trentin, B., & Mamoun, R. Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.28.357137 · Cited by 24
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityPreprint
Joyce, M. G., Chen, W.-H., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Chang, W., Peterson, C. E., Martinez, E., Morrison, E. B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.443331 · Cited by 23
Discovery and characterization of a pan-betacoronavirus S2-binding antibody
Johnson, N. V., Wall, S. C., Kramer, K. J., Holt, C., Periasamy, S., Richardson, S. I., Manamela, N. P., Suryadevara, N., Andreano, E., Paciello, I., et al. (2024) · Structure · doi:10.1016/j.str.2024.08.022 · Cited by 26
Self-citationHendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 24
Gene therapy avenues and COVID-19 vaccines
Abed, O. S. A. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00136-6 · Cited by 23
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 23
Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape
Kunkel, G., Madani, M., White, S. J., Verardi, P. H., & Tarakanova, A. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.11.009 · Cited by 23
Song, S., Kim, H., Jang, E. Y., Jeon, H.-M., Diao, H., Khan, M. R. I., Lee, M., Lee, Y. J., Nam, J., Kim, S., et al. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13908 · Cited by 24
Zhou, J., Liu, Z., Zhang, G., Xu, W., Xing, L., Lu, L., Wang, Q., & Jiang, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28172 · Cited by 24
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
Akache, B., Renner, T. M., Stuible, M., Rohani, N., Donates, Y. C., Deschatelets, L., Dudani, R., Harrison, B. A., Gervais, C., Hill, J. J., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00540-7 · Cited by 24
Huang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 23
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
Lee, J., Stewart, C., Schäfer, A., Leaf, E. M., Park, Y.-J., Asarnow, D., Powers, J. M., Treichel, C., Sprouse, K. R., Corti, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49656-5 · Cited by 23
Lai, C.-Y., To, A., Wong, T. A. S., Lieberman, M. M., Clements, D. E., Senda, J. T., Ball, A. H., Pessaint, L., Andersen, H., Furuyama, W., et al. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100126 · Cited by 24
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.096511 · Cited by 23
Self-citationRoth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines · doi:10.3390/vaccines10081251 · Cited by 22
Wang, Y., Liu, S., Li, B., Sun, X.-Y., Pan, Q., Zheng, Y., Liu, J., Zhao, Y., Wang, J., Liu, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336239 · Cited by 23
COVID-19 clinical presentation, management, and epidemiology: a concise compendium
Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 26
Emameh, R. Z., Nosrati, H., & Taheri, R. A. (2020) · Biological Procedures Online · doi:10.1186/s12575-020-00121-9 · Cited by 22
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
Tostanoski, L. H., Gralinski, L. E., Martinez, D. R., Schaefer, A., Mahrokhian, S. H., Li, Z., Nampanya, F., Wan, H., Yu, J., Chang, A., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00974-21 · Cited by 22
Kuo, C., Yang, T., Chien, Y.-C., Yu, P., Hsu, S. D., & Khoo, K. (2021) · Glycobiology · doi:10.1093/glycob/cwab102 · Cited by 23
Pellegrinelli, R. P., Yue, L., Carrascosa, E., Faleh, A. B., Warnke, S., Bansal, P., & Rizzo, T. R. (2022) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00043 · Cited by 22
Hashimoto, M., Nagata, N., Homma, T., Maeda, H., Dohi, K., Seki, N. M., Yoshihara, K., Iwata‐Yoshikawa, N., Shiwa-Sudo, N., Sakai, Y., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.081 · Cited by 20
Dosey, A. M., Ellis, D., Boyoglu-Barnum, S., Syeda, H., Saunders, M., Watson, M. J., Kraft, J. C., Pham, M. N., Guttman, M., Lee, K. K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113553 · Cited by 22
Addetia, A., Stewart, C., Seo, A. J., Sprouse, K. R., Asiri, A. Y., Al-Mozaini, M., Memish, Z. A., Alshukairi, A. N., & Veesler, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114530 · Cited by 19
ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses
Catanzaro, N., Wu, Z., Fan, C., Jefferson, V. A., Abdelgadir, A., Schäfer, A., Yount, B. L., Björkman, P. J., Baric, R. S., & Letko, M. C. (2025) · Nature Communications · doi:10.1038/s41467-025-60286-3 · Cited by 38
Challenges and Issues of Anti-SARS-CoV-2 Vaccines
Blumental, S., & Debré, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.664179 · Cited by 22
Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic
Chawla, H., Jossi, S. E., Faustini, S. E., Samsudin, F., Allen, J. D., Watanabe, Y., Newby, M. L., Marcial‐Juárez, E., Lamerton, R. E., McLellan, J. S., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167332 · Cited by 19
Self-citationThe trillion dollar vaccine gap
Pecetta, S., Tortorice, D. L., Scorza, F. B., Pizza, M., Dougan, G., Hatchett, R. J., BLACK, S. B., Bloom, D. E., & Rappuoli, R. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn4342 · Cited by 20
van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S.-V., Tejjani, K., Guerra, D., Kempers, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07590-w · Cited by 21
Transient Expression of Glycosylated SARS-CoV-2 Antigens in Nicotiana benthamiana
Ruocco, V., & Strasser, R. (2022) · Plants · doi:10.3390/plants11081093 · Cited by 24
Lazebnik, Y. A. (2021) · Oncotarget · doi:10.18632/oncotarget.28088 · Cited by 22
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Rando, H. M., Lordan, R., Lee, A. J., Naik, A. S., Wellhausen, N., Sell, E., Kolla, L., Gitter, A., Greene, C. S., Bansal, V., et al. (2023) · mSystems · doi:10.1128/msystems.00927-22 · Cited by 22
Chen, C., Yang, L., Chang, W., Huang, Y., Chiu, C., Shih, S., Huang, C., & Huang, K.-Y. A. (2022) · Nature Communications · doi:10.1038/s41467-022-33146-7 · Cited by 19
Cryo-EM structures of prefusion SIV envelope trimer
Gorman, J., Wang, C., Mason, R. D., Nazzari, A. F., Welles, H. C., Zhou, T., Bess, J. W., Bylund, T., Lee, M., Tsybovsky, Y., et al. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00852-1 · Cited by 21
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Fukushi, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37128-1 · Cited by 26
Karim, M. R., Morshed, M. N., Iqbal, S., Mohammad, S., Mathiyalagan, R., Yang, D., Kim, Y. J., Song, J., & Yang, D. U. (2023) · Biomolecules · doi:10.3390/biom13111678 · Cited by 21
Zhang, K., Li, S., Pintilie, G. D., Chmielewski, D., Schmid, M. F., Simmons, G., Jin, J., & Chiu, W. (2020) · QRB Discovery · doi:10.1017/qrd.2020.16 · Cited by 21
Barre, A., Damme, E. J. M. V., Klonjkowski, B., Simplicien, M., Sudor, J., Benoist, H., & Rougé, P. (2022) · Cells · doi:10.3390/cells11030339 · Cited by 21
SARS-CoV-2 spike conformation determines plasma neutralizing activityPreprint
Bowen, J. E., Walls, A. C., Joshi, A., Sprouse, K. R., Stewart, C., Tortorici, M. A., Franko, N., Logue, J. K., Mazzitelli, I. G., Tilles, S. W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473391 · Cited by 21
A general computational design strategy for stabilizing viral class I fusion proteins
Gonzalez, K. J., Huang, J., Criado, M. F., Banerjee, A., Tompkins, S. M., Mousa, J. J., & Strauch, E.-M. (2024) · Nature Communications · doi:10.1038/s41467-024-45480-z · Cited by 20
Structure-Based and Rational Design of a Hepatitis C Virus Vaccine
Guest, J. D., & Pierce, B. G. (2021) · Viruses · doi:10.3390/v13050837 · Cited by 20
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
Velusamy, P., Kiruba, K., Su, C., Arun, V., Anbu, P., Gopinath, S. C. B., & Vaseeharan, B. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101648 · Cited by 20
Sáez‐Llorens, X., Lanata, C. F., Aranguren, E., Celis, C. R., Cornejo, R., DeAntonio, R., Ecker, L., Garrido, D., Gil, A. I., Gonzales, M., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100189 · Cited by 20
Strategies for the Management of Spike Protein-Related Pathology
Halma, M. T. J., Plothe, C., Marik, P. E., & Lawrie, T. A. (2023) · Microorganisms · doi:10.3390/microorganisms11051308 · Cited by 22
Dayer, M. R. (2020) · Preprints.org · doi:10.20944/preprints202005.0020.v1 · Cited by 21
A simple protein-based surrogate neutralization assay for SARS-CoV-2Preprint
Abe, K. T., Li, Z., Samson, R., Samavarchi-Tehrani, P., Valcourt, E. J., Wood, H., Budylowski, P., Dupuis, A. P., Girardin, R. C., Rathod, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.10.197913 · Cited by 20
Johnson, B. A., Graham, R. L., & Menachery, V. D. (2017) · Virology · doi:10.1016/j.virol.2017.12.009 · Cited by 19
Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2
Saadi, F., Pal, D., & Sarma, J. D. (2021) · Annals of Neurosciences · doi:10.1177/09727531211023755 · Cited by 17
Zamane, S. A., Nobel, F. A., Jebin, R. A., Amin, M. A., Somadder, P. D., Antora, N. J., Hossain, M. I., Islam, M. J., Ahmed, K., & Moni, M. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100781 · Cited by 21
SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 19
Palladino, G., Chang, C. W., Lee, C., Music, N., de Souza, I. P., Nolasco, J., Amoah, S., Suphaphiphat, P., Otten, G. R., Settembre, E. C., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.013 · Cited by 19
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env
Hodge, E. A., Naika, G. S., Kephart, S. M., Nguyen, A., Zhu, R., Benhaim, M. A., Guo, W., Moore, J. P., Hu, S., Sanders, R. W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104449 · Cited by 22
Huffman, A., Ong, E., Hur, J., D’Mello, A., Tettelin, H., & He, Y. O. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac190 · Cited by 20
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Kovalenko, A. O., Ryabchevskaya, E. M., Evtushenko, E. A., Nikitin, N. A., & Karpova, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021701 · Cited by 21
Metadata
- Authors
- Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & McLellan, J. S.
- Affiliations
- Scripps Research Institute (US)
- Dartmouth College (US)
- National Institute of Allergy and Infectious Diseases (US)
- Vanderbilt University Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Pallesen, Jesper
- Wang, Nianshuang
- Corbett, Kizzmekia S.
- Ward, Andrew B.
- McLellan, Jason S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-08-14
- Volume
- 114
- Issue
- 35
- Pages
- E7348-E7357
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5584442
- OpenAlex
- W2750464792
- Cited by
- 1,073
- References
- 89
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 98 · 2023: 127 · 2022: 174 · 2021: 275 · 2020: 220 · 2019: 31 · 2018: 17 · 2017: 6
- FWCI
- 57.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI127521)
- HHS | NIH | National Institute of General Medical Sciences (P20GM113132)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI005125)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- MERS-CoV, spike protein, structure-based vaccine design, neutralizing antibodies, receptor binding domain, receptor recognition, membrane fusion mechanism, coronavirus vaccines
- MeSH terms
- Animals, Antibodies, Viral, Coronaviridae, Humans, Immunoglobulin G, Mice, Inbred BALB C, Protein Binding, Protein Conformation, Receptors, Virus, Structure-Activity Relationship, Vaccination, Viral Vaccines, Coronavirus Infections, Crystallography, X-Ray, Immunity, Humoral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
